title: Potential therapeutic value of TRPV1 and TRPA1 in diabetes mellitus and obesity.
abstract: Diabetes mellitus and obesity, which is a major risk factor in the development of type 2 diabetes mellitus, have reached epidemic proportions worldwide including the USA. The current statistics and forecasts, both short- and long-term, are alarming and predict severe problems in the near future. Therefore, there is a race for developing new compounds, discovering new receptors, or finding alternative solutions to prevent and/or treat the symptoms and complications related to obesity and diabetes mellitus. It is well demonstrated that members of the transient receptor potential (TRP) superfamily play a crucial role in a variety of biological functions both in health and disease. In the recent years, transient receptor potential vanilloid type 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1) were shown to have beneficial effects on whole body metabolism including glucose homeostasis. TRPV1 and TRPA1 have been associated with control of weight, pancreatic function, hormone secretion, thermogenesis, and neuronal function, which suggest a potential therapeutic value of these channels. This review summarizes recent findings regarding TRPV1 and TRPA1 in association with whole body metabolism with emphasis on obese and diabetic conditions.
authors.affiliation: Department of Physiology, School of Medicine, Tulane University, 1430 Tulane Ave., New Orleans, LA, 70112, USA.
authors.forename: Andrei V
authors.initials: AV
authors.lastname: Derbenev
authors.affiliation: Department of Physiology, School of Medicine, Tulane University, 1430 Tulane Ave., New Orleans, LA, 70112, USA. azsombo@tulane.edu.|Department of Medicine, Endocrinology Section, School of Medicine, Tulane University, 1430 Tulane Ave., New Orleans, LA, 70112, USA. azsombo@tulane.edu.
authors.forename: Andrea
authors.initials: A
authors.lastname: Zsombok
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism; D000818:Animals; D001341:Autonomic Nervous System / Q000187:drug effects / Q000378:metabolism; D015220:Calcium Channels / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000378:metabolism* / Q000628:therapy; D004035:Diet Therapy; D019587:Dietary Supplements; D054439:Ghrelin / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism; D006801:Humans; D008024:Ligands; D009419:Nerve Tissue Proteins / Q000819:agonists / Q000378:metabolism*; D009765:Obesity / Q000378:metabolism* / Q000628:therapy; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D000074025:TRPA1 Cation Channel; D050916:TRPV Cation Channels / Q000819:agonists / Q000378:metabolism*; D050051:Transient Receptor Potential Channels / Q000819:agonists / Q000378:metabolism*
chemical_list: D015220:Calcium Channels; D054439:Ghrelin; D008024:Ligands; D009419:Nerve Tissue Proteins; D000074025:TRPA1 Cation Channel; C473350:TRPA1 protein, human; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human; D050051:Transient Receptor Potential Channels; D052216:Glucagon-Like Peptide 1
keywords: Diabetes; Glucose homeostasis; Metabolism; Obesity; TRPA1; TRPV1